WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that an abstract highlighting the company’s pan-KIT and PDGFRα inhibitor, DCC-2618, has been selected for presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting, taking place April 1-5, 2017 in Washington D.C. Filip Janku, M.D., Ph.D., Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center will present this late-breaking abstract. Details of the poster presentation on DCC-2618 are as follows:
Poster Title: Translational Research in a Phase 1
Proof-of-Concept Study Supports that DCC-2618 is a pan-KIT Inhibitor.
Author: Filip Janku, M.D., Ph.D.
Session: LBPO.CL01 - Late-Breaking Research: Clinical Research 1
Abstract #: LB-039 / 2
Date & Time: Monday, April 3, 2017, 8:00 AM – 12:00 PM
“We are very pleased to present these important data at the upcoming AACR Annual Meeting demonstrating scientific translation from preclinical assays and cancer models to Phase 1 human clinical study with DCC-2618,” said Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer. “These encouraging data build upon and are supportive of the impressive initial clinical data reported on DCC-2618 last year at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.”
DCC-2618 is currently in a first-in-human Phase 1 clinical trial. DCC-2618 is a pan-KIT and PDGFRα switch control kinase inhibitor in clinical development for the treatment of genetically-defined cancers, including gastrointestinal stromal tumors (GIST), glioblastoma multiforme, systemic mastocytosis and other KIT and/or PDGFRα-driven cancers.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their response to treatment.